Effects of vinpocetine combined with batroxobin on blood glucose, hearing, and serum levels of visfatin and ENA-78 in elderly patients with type 2 diabetes mellitus and deafness was written by Wang, Jing;Zhu, Lu-ming;Yang, Bing;Li, Li;Jiang, Li-li;Le, Ting;Tu, Xiao-hong. And the article was included in Shiyong Yaowu Yu Linchuang in 2021.Recommanded Product: 42971-09-5 This article mentions the following:
Objective To investigate the effects of vinpocetine combined with batroxobin on hearing, blood glucose, and serum levels of visfatin and ENA-78 in elderly patients with type 2 diabetes mellitus and deafness. Methods A total of 94 elderly patients with type 2 diabetes mellitus with deafness receiving treatment from July 2016 to July 2019 were randomly divided into observation group and control group by random number table method, 47 cases each. All patients received hypoglycemc treatment and the basic treatment of improved cochlear microcirculation and nerve nutritional. Both groups were treated with batroxobin injection by i.v. dripping 10 BU/time, once every 2 days, for 10 days. The observation group was addnl. treated with vinpocetine by i.v. infusion, 20 mg/time, once every 2 days, for 10 days. The total effective rate, fasting blood glucose and pure tone threshold at different time points before and after treatment, serum levels of visfatin and ENA-78 before and after treatment, high-cut viscosity of whole blood, low-cut viscosity of whole blood and plasma viscosity were compared. The correlation between pure tone threshold and serum levels of visfatin and ENA-78 was analyzed. Results The total effective rate of observation group was 89.36%, which was higher than 72.34% of the control group (P<0.05). The fasting blood glucose before treatment was comparable between the two groups (P>0.05). At different time points after treatment, the fasting blood glucose of the two groups was lower than that before treatment (P<0.05), but the difference between the two groups was not statistically significant (P>0.05), and no hypoglycemia events were observed during the treatment. At different time points after treatment, the pure tone hearing threshold of the two groups was lower than that before treatment (P<0.05). The pure tone thresholds of the observation group at 8 and 10 days after treatment were (52.60±3.11) dB, (48.42±2.02) dB, which were lower than those of the control group [(55.71±3.32) dB, (52.61±2.97) dB] with statistical significance (P<0.05). After 10 days of treatment, serum visfatin and ENA-78, whole blood high-cut viscosity, whole blood low-cut viscosity and plasma viscosity of the two groups were lower than those before treatment (P<0.05), and the decrease of the observation group was even larger (P< 0.05). There was a significant pos. correlation between pure tone threshold and serum visfatin (r=0.75, P<0.001), and a pos. correlation with serum ENA-78 (r=0.72, P<0.001). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Batroxobin combined with vinpocetine can play a synergistic role in the treatment of elderly type 2 diabetes with deafness, promoting the improvement of blood rheol. and down-regulating serum visfatin, ENA-78, which promotes the recovery of hearing. Its effect is better than single batroxobin, and has higher security. In the experiment, the researchers used many compounds, for example, (41S,13aS)-Ethyl 13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (cas: 42971-09-5Recommanded Product: 42971-09-5).
(41S,13aS)-Ethyl 13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (cas: 42971-09-5) belongs to naphthyridine derivatives. Six naphthyridine isomers exist, based on the positions of the nitrogen atoms; they can be in the 1,5, 1,6, 1,7, 1,8, 2,6, or 2,7 positions. 1,6-Naphthyridine and some of its derivatives have been reported to have medicinal, electronic, and catalytic properties. But none of these investigations has yet resulted in any practical applications. Very few metal complexes of naphthyridines other than 1,8-naphthyridine have been described.Recommanded Product: 42971-09-5
Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem